IOBTIO Biotech, Inc.

Nasdaq iobiotech.com


$ 0.95 $ 0.17 (22.55 %)    

Tuesday, 17-Sep-2024 13:01:25 EDT
QQQ $ 473.53 $ -2.44 (-0.51 %)
DIA $ 416.64 $ -1.35 (-0.32 %)
SPY $ 562.89 $ -2.24 (-0.4 %)
TLT $ 100.93 $ -0.46 (-0.45 %)
GLD $ 236.97 $ -1.01 (-0.42 %)
$ 0.7752
$ 0.75
$ 0.95 x 500
$ 1.07 x 600
$ 0.75 - $ 0.95
$ 0.73 - $ 2.10
5,340,725
na
51.07M
$ 1.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 12-17-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-maintains-overweight-on-io-biotech-raises-price-target-to-6

Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:IOBT) with a Overweight and raises the price target fro...

 hc-wainwright--co-reiterates-buy-on-io-biotech-maintains-12-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech (NASDAQ:IOBT) with a Buy and maintains $12 price target.

 reported-saturday-io-biotech-announced-data-from-phase-2-basket-trial-of-io102-io103-therapeutic-cancer-vaccine-candidate-in-combination-with-mercks-keytruda-at-the-2024-esmo-congress

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous C...

 piper-sandler-maintains-overweight-on-io-biotech-maintains-10-price-target

Piper Sandler analyst Christopher Raymond maintains IO Biotech (NASDAQ:IOBT) with a Overweight and maintains $10 price target.

 morgan-stanley-maintains-overweight-on-io-biotech-lowers-price-target-to-4

Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:IOBT) with a Overweight and lowers the price target fro...

 hc-wainwright--co-reiterates-buy-on-io-biotech-maintains-12-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech (NASDAQ:IOBT) with a Buy and maintains $12 price target.

 hc-wainwright--co-reiterates-buy-on-io-biotech-maintains-12-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech (NASDAQ:IOBT) with a Buy and maintains $12 price target.

 hc-wainwright--co-maintains-buy-on-io-biotech-raises-price-target-to-12

HC Wainwright & Co. analyst Emily Bodnar maintains IO Biotech (NASDAQ:IOBT) with a Buy and raises the price target from ...

 hc-wainwright--co-reiterates-buy-on-io-biotech-maintains-8-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech (NASDAQ:IOBT) with a Buy and maintains $8 price target.

 io-biotech-q4-eps-040-misses-039-estimate

IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) ...

 top-5-health-care-stocks-that-may-crash-this-month

As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION